Abstract 239P
Background
With the induction of molecular targeted therapy and immune checkpoint inhibitors, treatment strategies for systemic treatment of metastatic clear cell renal cell carcinoma (mCCRCC) have been changed with improved survival. However, for those patients diagnosed as metastatic non-clear cell renal cell carcinoma (mNCRCC), systemic therapy designed and approved for mCCRCC have been used because no validated systemic therapy exists. This retrospective study aimed to identify prognostic factors for patients with mNCRCC treated with systemic therapy.
Methods
A total of 270 patients were reviewed. Among them, 41 patients who pathologically diagnosed as mNCRCC and received systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The progression free survival (PFS) and overall survival (OS) between mNCRCC and mCCRCC patients were compared. The OS for patients with mNCRCC was further investigated with univariate and multivariate Cox’s proportional hazards regression models.
Results
After a median follow-up of 31.3 months after first-line treatment initiation, the median PFS was 3.3 and 20.8 months for mNCRCC and mCCRCC, respectively (p<0.0001). The median OS was 19.6 and 54.4 months for mNCRCC and mCCRCC, respectively (p<0.0001). For patients with mNCRCC, univariate Cox proportional hazards model analyses revealed that the duration of first-line treatment (p<0.0001), the time to first-line treatment within 1 year (p=0.0201), high corrected serum calcium (p=0.0006), high neutrophil count (p=0.0003), and the baseline CRP level (p=0.0034) were significantly correlated with shorter OS, respectively. Furthermore, a multivariate analysis revealed the duration of first-line treatment (Hazard ratio (HR): 0.89, 95% CI: 0.81-0.97, p=0.007), the high corrected serum calcium (HR: 4.04, 95% CI: 1.58-10.37, p=0.004), and the baseline CRP level (HR: 1.15, 95% CI: 1.05-1.25, p=0.002) were independent predictors for OS in mNCRCC patients.
Conclusions
Patients with mNCCC resulted in shorter PFS and OS. Elevated baseline C-reactive protein, a prognostic factor for mCCRCC, was also correlated with shorter OS in mNCRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract